rob aarnoutse, pharmd, phd radboudumc …scientific findings in the tb clinical pharmacology field....
TRANSCRIPT
12TH INTERNATIONAL WORKSHOP ON
LONDON, UK • 10 SEPTEMBER 2019
CLINICAL PHARMACOLOGYOF TUBERCULOSIS DRUGS
The aim of this abstract-driven workshop is to make a significant contribution to the optimization of TB treatment, by bringing experts together and having them present and discuss the latest important scientific findings in the TB clinical pharmacology field. Additionally, scientific, regulatory or strategy issues that are highly relevant to the optimization of TB treatment will be exchanged and discussed. We look forward to seeing you in London!
WHO SHOULD ATTEND?
• Pharmacists/pharmacologists involved in clinical management of TB-infected patients
• Preclinical and clinical pharmacology researchers from academia and Industry
• PhD and PharmD students• Representatives from regulatory or non-governmental
organizations active in the TB-field
ORGANIZING COMMITTEE
Rob Aarnoutse, PharmD, PhD Radboudumc The Netherlands
Geraint Davis, MD University of Liverpool United Kingdom
Helen McIlleron, MBCHB, PhD University of Cape Town South Africa
Jerry Nedelman, PhD TB Alliance USA
Eric Nuermberger, MD Johns Hopkins University USA
Charles Peloquin, PharmD University of Florida USA
Registration and information: www.expertmedicalevents.com
ORGANIZED BY
FORMAT
This one-day program consists of two to three plenary lectures from invited speakers, and ample time for oral and poster abstract presen-tations.
There is also one highly-rated guided poster tour after the lunch break, where delegates are invited to further explore the content of the accepted abstracts in an informal setting.
Our workshop involves a strong community of clinical pharmaco-logists and other healthcare professionals working in the TB-field. Also, the workshop provides an independent scientific platform to discuss controversial topics and views.
JOIN US AT THE 12TH EDITION OF:
ABOUT THE WORKSHOP
INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF TUBERCULOSIS DRUGS
The treatment of Tuberculosis (TB) is becoming a challenge worldwide. All around the world experts in the field are involved in intensive research to be able to cope with the various concerns with regard to treatment.
The aim of this abstract-driven workshop is to make a significant contribution to the optimization of TB treatment, by bringing experts together and having them present and discuss the latest important scientific findings in the TB clinical pharmacology field. Additionally, scientific, regulatory or strategy issues that are highly relevant to the optimization of TB treatment will be exchanged and discussed.
Topics will include:- Pharmacokinetics and pharmacodynamics of new TB drugs- Pharmacokinetics and pharmacodynamics of approved TB drugs- Pharmacokinetic – pharmacodynamic modeling- Drug-drug and drug-disease internactions- New TB drug development tools- New developments in pediatric TB- Interactions between TB and HIV drugs- Treatment of MDR- and XDR-TB
ABSTRACT SUBMISSION IS OPEN! SUBMIT YOUR ABSTRACT BEFORE 19 JULY 2019!FOR MORE INFORMATION VISIT WWW.EXPERTMEDICALEVENTS.COM
2018 EDITION IN NUMBERSDelegates from 14 countries43 abstract submissions20 oral abstract presentations